Brokerages expect that Heron Therapeutics Inc (NASDAQ:HRTX) will announce earnings of ($0.68) per share for the current quarter, Zacks reports. Four analysts have made estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.77). Heron Therapeutics reported earnings of ($0.54) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 25.9%. The business is expected to report its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.66) per share for the current year, with EPS estimates ranging from ($3.15) to ($2.22). For the next year, analysts forecast that the business will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.67) to ($0.83). Zacks’ EPS averages are an average based on a survey of research analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The business had revenue of $31.60 million during the quarter, compared to the consensus estimate of $28.04 million. During the same quarter in the previous year, the business posted ($1.09) EPS. The company’s revenue for the quarter was up 172.4% on a year-over-year basis.
In other news, Director Waage Christian acquired 1,400 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, May 15th. The shares were acquired at an average price of $18.04 per share, for a total transaction of $25,256.00. Following the transaction, the director now directly owns 1,400 shares of the company’s stock, valued at approximately $25,256. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Poyhonen acquired 3,000 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, May 22nd. The shares were purchased at an average price of $17.55 per share, for a total transaction of $52,650.00. Following the transaction, the director now directly owns 13,000 shares in the company, valued at $228,150. The disclosure for this purchase can be found here. Company insiders own 12.56% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Virginia Retirement Systems ET AL grew its position in Heron Therapeutics by 2.3% during the 1st quarter. Virginia Retirement Systems ET AL now owns 36,100 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 800 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Heron Therapeutics by 247.4% in the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,200 shares during the last quarter. Mackay Shields LLC grew its position in shares of Heron Therapeutics by 7.0% in the 4th quarter. Mackay Shields LLC now owns 23,975 shares of the biotechnology company’s stock valued at $622,000 after buying an additional 1,575 shares during the last quarter. Legal & General Group Plc grew its position in shares of Heron Therapeutics by 6.5% in the 4th quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 1,679 shares during the last quarter. Finally, Pearl River Capital LLC grew its position in shares of Heron Therapeutics by 1,900.0% in the 1st quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,900 shares during the last quarter.
Shares of HRTX traded down $0.39 during midday trading on Wednesday, hitting $17.44. The company’s stock had a trading volume of 970,371 shares, compared to its average volume of 981,711. Heron Therapeutics has a one year low of $16.20 and a one year high of $41.55. The company’s fifty day moving average price is $18.22. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. The company has a market cap of $1.38 billion, a PE ratio of -7.15 and a beta of 1.59.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: Cost of equity and a company’s balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.